Krilogy Financial LLC Sells 34,192 Shares of Boston Scientific Corporation $BSX

Krilogy Financial LLC lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 74.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,028 shares of the medical equipment provider’s stock after selling 34,192 shares during the period. Krilogy Financial LLC’s holdings in Boston Scientific were worth $763,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in the stock. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter worth $26,000. Swiss RE Ltd. purchased a new position in Boston Scientific in the fourth quarter valued at about $26,000. Garton & Associates Financial Advisors LLC bought a new position in Boston Scientific in the fourth quarter worth about $26,000. Bangor Savings Bank lifted its position in shares of Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund purchased a new stake in shares of Boston Scientific during the fourth quarter valued at about $29,000. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BSX. Oppenheimer set a $90.00 price objective on shares of Boston Scientific in a research report on Thursday, April 23rd. Jefferies Financial Group lowered their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday. Mizuho cut their price target on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a report on Monday, April 13th. Wolfe Research lowered Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Finally, Leerink Partners lowered their price objective on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $83.36.

Boston Scientific Stock Performance

Shares of BSX opened at $44.16 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The stock has a 50-day moving average of $52.87 and a two-hundred day moving average of $71.13. The stock has a market cap of $65.64 billion, a P/E ratio of 18.48, a P/E/G ratio of 0.85 and a beta of 0.56. Boston Scientific Corporation has a one year low of $43.89 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period in the prior year, the company earned $0.75 earnings per share. The company’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its board has approved a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig purchased 3,580 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director owned 25,359 shares in the company, valued at $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Cheryl Pegus acquired 1,770 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by company insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.